drugset / Trial / NCT01434576
Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, and pharmacokinetics of HGS1025 in patients with moderate to severe ulcerative colitis.
Timeline
- Start
- 2011-12
- Primary completion
- 2012-12
- Completion
- —
Outcome
Outcome not reported
Stopped (Business): “Sponsor withdrew study for business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HGS1025 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | HGS1025 | Monoclonal antibody | 10 mg/kg | Intravenous |